In KRAS-mutant PDAC, inflammatory mediators (e.g., cytokines, DAMPs, and immune cells) are involved in pro- or anti-tumor gene modulation to sustain a favorable inflammatory TME for tumor growth and development [87]. This evidence concerns the gene KRAS and neoplasm.